āļ§ัāļ™āļˆัāļ™āļ—āļĢ์āļ—ี่ 13 āđ€āļĄāļĐāļēāļĒāļ™ āļž.āļĻ. 2569

Diabetic Retinopathy: Pathogenesis & Clinical

Diabetic Retinopathy: Pathogenesis & Clinical


Pathogenesis

🔑 Key concept (high-yield)

  • Chronic hyperglycemia = driver āļŦāļĨัāļ
  • āļ—āļģāđƒāļŦ้āđ€āļิāļ” 2 āļāļĨāđ„āļāļŦāļĨัāļāđƒāļ™ retina

1.       vascular permeability macular edema

2.       capillary occlusion ischemia neovascularization


1. Pathophysiology overview

  • DR āđ€āļ›็āļ™ neurovascular unit disease (āđ„āļĄ่āđƒāļŠ่āđāļ„่ microangiopathy)
  • āđ€āļิāļ”āļˆāļēāļ interaction āļ‚āļ­āļ‡:
    • metabolic pathways
    • inflammation
    • microvascular injury
    • neurodegeneration

2. Early mechanisms (āļ่āļ­āļ™āļĄี lesion āđƒāļŦ้āđ€āļŦ็āļ™)

Metabolic / biochemical pathways

  • Polyol pathway (sorbitol accumulation)
  • Protein kinase C activation
  • Advanced glycation end products (AGEs)
    āļ—āļģāđƒāļŦ้:
  • oxidative stress
  • endothelial dysfunction
  • vascular permeability

Neurovascular dysfunction

  • microglial activation, cytokines, complement
  • blood-retinal barrier breakdown
  • ERG āļžāļš abnormal āđ„āļ”้āļ่āļ­āļ™ clinical DR

3. Structural retinal changes

  • Pericyte loss (hallmark)
  • Basement membrane thickening
  • Microaneurysm formation
  • capillary closure ischemia
    downstream:
  • macular edema
  • neovascularization
  • tractional retinal detachment

4. Microvascular & hemodynamic changes

  • Leukostasis (early finding) endothelial injury
  • Microthrombosis capillary occlusion
  • Loss of autoregulation
    retinal blood flow shear stress leakage edema

5. Key molecular pathways

5.1 Advanced glycation end products (AGEs)

  • cross-link collagen microvascular damage
  • activate RAGE ROS inflammation

5.2 Polyol pathway

  • sorbitol accumulation osmotic stress
  • NADPH oxidative stress
  • affect Na/K ATPase + signaling pathways

6. Growth factors (late stage)

ðŸ”ī VEGF (vascular endothelial growth factor) (most important)

  • induced by hypoxia
  • vascular permeability
  • neovascularization

🟠 IGF-1

  • synergize with VEGF
  • associated with progression to proliferative DR

Others

  • Erythropoietin
  • PDGF, FGF, angiopoietin-Tie2
    contribute to angiogenesis

7. Clinical correlation

Macular edema

  • āļˆāļēāļ vascular leakage
  • mechanism: VEGF + hemodynamic stress

Proliferative DR (PDR)

  • āļˆāļēāļ retinal ischemia VEGF surge
  • complications:
    • vitreous hemorrhage
    • tractional RD
    • neovascular glaucoma

8. Glycemic control (very high yield)

  • DCCT / UKPDS
    • āļĨāļ” A1C āļĨāļ” DR āļ­āļĒ่āļēāļ‡āļĄีāļ™ัāļĒāļŠāļģāļ„ัāļ
    • A1C 1% DR ~37%
  • A1C <7% progression āļ•่āļģāļĄāļēāļ

👉 āđāļ•่:

  • rapid glucose lowering early worsening DR

9. Risk modifiers

āđ€āļžิ่āļĄ risk

  • duration DM
  • poor glycemic control
  • hypertension
  • nephropathy (albuminuria)
  • genetic susceptibility

Protective / modifying factors

  • anti-angiogenic factors (āđ€āļŠ่āļ™ PEDF)
  • RBP3 (āļĨāļ” VEGF + inflammation)
  • genetic resistance

10. Clinical pearls

  • DR āđ€āļĢิ่āļĄāļˆāļēāļ functional + molecular change āļ่āļ­āļ™ structural lesion
  • pericyte loss + microaneurysm = earliest histologic change
  • VEGF = target āļŦāļĨัāļāļ‚āļ­āļ‡ treatment (anti-VEGF)
  • macular edema āļ•้āļ­āļ‡āļĄี PDR
  • DR āđāļĨāļ° nephropathy share pathogenesis screen āļĢ่āļ§āļĄāļัāļ™

🔚 Bottom line

  • DR = multifactorial neurovascular disease driven by chronic hyperglycemia
  • Early: metabolic + inflammation
  • Late: ischemia VEGF neovascularization
  • glycemic control = intervention āļ—ี่āļŠāļģāļ„ัāļāļ—ี่āļŠุāļ”

Classification, Clinical features & Natural history

🔑 Key points

  • DR āđ€āļ›็āļ™ leading cause āļ‚āļ­āļ‡ vision loss āđƒāļ™āļ§ัāļĒāļ—āļģāļ‡āļēāļ™
  • āļĄัāļ asymptomatic āļˆāļ™ late stage
  • visual loss āđ€āļิāļ”āļˆāļēāļ:
    • macular edema (ME)
    • vitreous hemorrhage
    • tractional retinal detachment
    • neovascular glaucoma

1. Classification (āļŠāļģāļ„ัāļāļĄāļēāļāđƒāļ™ clinical decision)

1.1 Nonproliferative DR (NPDR)

āļĨัāļāļĐāļ“āļ°

  • microaneurysm (earliest sign)
  • dot/blot hemorrhage
  • hard exudate
  • cotton wool spots
  • venous beading / IRMA

āđāļš่āļ‡ severity

  • Mild Moderate Severe Very severe

Risk progression PDR (1 āļ›ี)

  • Mild: ~5%
  • Moderate: ~15%
  • Severe: ~52%
  • Very severe: ~75%

👉 Clinical implication: āļāļģāļŦāļ™āļ” follow-up interval + timing of treatment


1.2 Proliferative DR (PDR)

Definition

  • āļĄี neovascularization (NVD/NVE)

Complications

  • vitreous hemorrhage
  • fibrosis tractional RD
  • neovascular glaucoma

ðŸ”ī High-risk PDR (āļ•้āļ­āļ‡ treat āđ€āļĢ็āļ§)

  • NVD > 1/3–1/2 disc
  • NVD (disc) + hemorrhage
  • NVE (elsewhere) + hemorrhage

👉 untreated 60% severe vision loss in 5 āļ›ี


1.3 Diabetic Macular Edema (DME)

  • āđ€āļิāļ”āđ„āļ”้āļ—ุāļ stage
  • āđāļš่āļ‡:
    • center-involving
    • non-center

👉 cause āļŦāļĨัāļāļ‚āļ­āļ‡ vision loss āđƒāļ™ NPDR


2. Clinical manifestations

Early

  • āļĄัāļ āđ„āļĄ่āļĄีāļ­āļēāļāļēāļĢ

Late symptoms

  • blurred vision (DME)
  • floaters (vitreous hemorrhage)
  • curtain-like vision loss (RD)
  • acute vision drop

3. Ophthalmologic findings (high yield)

Early lesions

  • microaneurysm
  • hard exudate (lipid leakage)
  • capillary leakage

Ischemia-related

  • cotton wool spots (nerve fiber infarct)
  • venous beading
  • IRMA

Advanced

  • neovascularization
  • vitreous hemorrhage
  • tractional RD

4. Pathophysiologic-clinical link

2 mechanisms āļŠāļģāļ„ัāļ:

1.       permeability edema (DME)

2.       vascular occlusion ischemia VEGF neovascularization (PDR)


5. Natural history

Type 1 DM

  • āđ€āļĢิ่āļĄ DR: 3–5 āļ›ีāļŦāļĨัāļ‡ diagnosis
  • ~āđ€āļืāļ­āļšāļ—ุāļāļ„āļ™āļĄี DR āđƒāļ™ 15–20 āļ›ี

Type 2 DM

  • 50–80% āļĄี DR āđƒāļ™ 20 āļ›ี
  • āļšāļēāļ‡āļ„āļ™āļĄีāļ•ั้āļ‡āđāļ•่ diagnosis (delay diagnosis)

6. Impact of glycemic control

Intensive control

  • incidence + severity DR
  • āļĄี legacy effect (benefit āļĒāļēāļ§)

⚠️ Early worsening

  • āļŠ่āļ§āļ‡āđāļĢāļāļ‚āļ­āļ‡ intensive therapy
  • mechanism:
    • plasma volume
    • IGF-1
      āļ•้āļ­āļ‡ monitor āđƒāļāļĨ้āļŠิāļ”

7. Special situations

ðŸĪ° Pregnancy

  • risk progression (16–85%)
  • risk āļ–้āļē:
    • baseline DR āļĄāļēāļ
    • A1C āļŠูāļ‡
    • āļĨāļ” A1C āđ€āļĢ็āļ§

👉 āļ•้āļ­āļ‡ screen āļš่āļ­āļĒāļ‚ึ้āļ™ + follow postpartum 1 āļ›ี


8. Systemic association

  • DR = marker āļ‚āļ­āļ‡ microvascular + macrovascular disease
  • risk:
    • MI
    • stroke
    • CVD death
  • PDR risk āļŠูāļ‡āļŠุāļ”

9. Clinical pearls (āļŠāļ­āļš/āđƒāļŠ้āļ‡āļēāļ™āļˆāļĢิāļ‡)

  • DR āļĄัāļ āđ„āļĄ่āļĄีāļ­āļēāļāļēāļĢ āļ•้āļ­āļ‡ screen
  • microaneurysm = earliest clinical sign
  • DME = cause āļŦāļĨัāļāļ‚āļ­āļ‡ visual loss āđƒāļ™ NPDR
  • PDR = sight-threatening stage
  • severity āļ‚āļ­āļ‡ NPDR = predictor āļ‚āļ­āļ‡ progression
  • DR severity correlate āļัāļš systemic disease burden

🔚 Bottom line

  • DR progression:
    NPDR
    ischemia VEGF PDR complications
  • outcome āļ‚ึ้āļ™āļัāļš:
    • glycemic control
    • early detection
    • timely treatment

 

āđ„āļĄ่āļĄีāļ„āļ§āļēāļĄāļ„ิāļ”āđ€āļŦ็āļ™:

āđāļŠāļ”āļ‡āļ„āļ§āļēāļĄāļ„ิāļ”āđ€āļŦ็āļ™